Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATIR101 Dose-Finding Study in Hematologic Malignancies Post-Haploidentical HSCT
NCT00993486Phase 2Completed
- Sponsor
- Kiadis Pharma
- Start
- Jan 2005
- Primary completion
- Oct 2008
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ATIR101 in hematologic malignancy, sponsored by Kiadis Pharma. Started Jan 2005; status: completed.
02
Drugs
ATIR101
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT00993486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00993486.